Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00043550 · ClinicalTrials.gov registry record · Phase 3
Treatments for Depression: Drug Versus Psychotherapy
A Phase 3 study of Depression, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 3
- Development phase
- 156
- Enrollment target
- 1
- Study location
NCT00043550: Completed Phase 3 study of Depression, sponsored by University of Pennsylvania.
NCT00043550 is a Phase 3 study of Depression that has completed, run by University of Pennsylvania. The registered enrollment target is 156 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00043550, a Phase 3 study of Depression, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 156 participants
- Enrollment target
- 1
- Study location
Study Summary
This 4-8 month study, with a 2-year follow up period, will compare sertraline (Zoloft®), venlafaxine (Effexor®), supportive-expressive psychotherapy, and placebo to determine which is more effective in treating major depression.
Primary Outcome
Hamilton Rating Scale for Depression (HRSD) (Hamilton, 1960). We used the 17-item version of the 27-item HRSD, a measure of depression severity. The Structured Interview Guide was used to conduct the interviews (SIGH-D; Williams, 1988). The reliability and validity of the HRSD are well documented (Rabkin \& Klein, 1987). Interjudge reliability as assessed by interclass correlations was .92 in our sample. Total 17-item scores could range from 17-48 with higher scores indicating greater distress.
Conditions Studied
Interventions
- DRUG Sertraline
- DRUG Venlafaxine
- BEHAVIORAL Supportive Expressive Therapy
- DRUG Pill Placebo
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2001-11 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
What the finished NCT00043550 record still lists
NCT00043550 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 4 interventions - of which Sertraline is the first listed.
NCT00043550 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00043550 about?
NCT00043550 is a clinical study titled "Treatments for Depression: Drug Versus Psychotherapy". This 4-8 month study, with a 2-year follow up period, will compare sertraline (Zoloft®), venlafaxine (Effexor®), supportive-expressive psychotherapy, and placebo to determine which is more effective in treating major depression.
What is the current status of trial NCT00043550?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 156 participants. The study started on 2001-11. Estimated completion is 2009-06.
What conditions does trial NCT00043550 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT00043550?
The interventions under investigation include: Sertraline (DRUG), Venlafaxine (DRUG), Supportive Expressive Therapy (BEHAVIORAL), Pill Placebo (DRUG).
Who is sponsoring clinical trial NCT00043550?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00043550 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00043550's enrollment target sits among peer trials
156 244th of 679 higher than 435 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Behavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care
RECRUITING · Phase 3
-
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
RECRUITING · Phase 3
-
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
RECRUITING · Phase 3
-
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
RECRUITING · Phase 3
-
Creatine for Depressed Male and Female Methamphetamine Users
RECRUITING · Phase 3
-
E-Mindfulness Approaches for Living After Breast Cancer
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia